Dispersing biofilms with engineered enzymatic bacteriophage

被引:596
作者
Lu, Timothy K.
Collins, James J.
机构
[1] Boston Univ, Ctr BioDynam, Boston, MA 02215 USA
[2] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA
[3] Harvard Univ, MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA
关键词
phage therapy; synthetic biology; BACTERIAL BIOFILMS; PHAGE; DNA; THERAPY; DISEASE; LIFE;
D O I
10.1073/pnas.0704624104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Synthetic biology involves the engineering of biological organisms by using modular and generalizable designs with the ultimate goal of developing useful solutions to real-world problems. One such problem involves bacterial biofilms, which are crucial in the pathogenesis of many clinically important infections and are difficult to eradicate because they exhibit resistance to antimicrobial treatments and removal by host immune systems. To address this issue, we engineered bacteriophage to express a biofilm-degrading enzyme during infection to simultaneously attack the bacterial cells in the biofilm and the biofilm matrix, which is composed of extracellular polymeric substances. We show that the efficacy of biofilm removal by this two-pronged enzymatic bacteriophage strategy is significantly greater than that of nonenzymatic bacteriophage treatment. Our engineered enzymatic phage substantially reduced bacterial biofilm cell counts by approximate to 4.5 orders of magnitude (approximate to 99.997% removal), which was about two orders of magnitude better than that of nonenzymatic phage. This work demonstrates the feasibility and benefits of using engineered enzymatic bacteriophage to reduce bacterial biofilms and the applicability of synthetic biology to an important medical and industrial problem.
引用
收藏
页码:11197 / 11202
页数:6
相关论文
共 51 条
[1]   Environmentally controlled invasion of cancer cells by engineered bacteria [J].
Anderson, JC ;
Clarke, EJ ;
Arkin, AP ;
Voigt, CA .
JOURNAL OF MOLECULAR BIOLOGY, 2006, 355 (04) :619-627
[2]   Synthetic biology: new engineering rules for an emerging discipline [J].
Andrianantoandro, Ernesto ;
Basu, Subhayu ;
Karig, David K. ;
Weiss, Ron .
MOLECULAR SYSTEMS BIOLOGY, 2006, 2 (1) :2006.0028
[3]  
[Anonymous], 2006, FED REGISTER, V71, P47729
[4]   Treatment of Clostridium difficile-associated disease:: old therapies and new strategies [J].
Aslam, S ;
Hamill, R ;
Musher, DM .
LANCET INFECTIOUS DISEASES, 2005, 5 (09) :549-557
[5]   Engineering life: Building a fab for biology [J].
Baker, David ;
Group, B. I. O. F. A. B. ;
Church, George ;
Collins, Jim ;
Endy, Drew ;
Jacobson, Joseph ;
Keasling, Jay ;
Modrich, Paul ;
Smolke, Christina ;
Weiss, Ron .
SCIENTIFIC AMERICAN, 2006, 294 (06) :44-51
[6]   Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].
Bartlett, John G. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764
[7]  
Boratynski J, 2004, CELL MOL BIOL LETT, V9, P253
[8]   The Calgary Biofilm Device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms [J].
Ceri, H ;
Olson, ME ;
Stremick, C ;
Read, RR ;
Morck, D ;
Buret, A .
JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (06) :1771-1776
[9]   Refactoring bacteriophage T7 [J].
Chan, Leon Y. ;
Kosuri, Sriram ;
Endy, Drew .
MOLECULAR SYSTEMS BIOLOGY, 2005, 1 (1) :2005.0018
[10]   Bacteriophage T4 multiplication in a glucose-limited Escherichia coli biofilm [J].
Corbin, BD ;
McLean, RJC ;
Aron, GM .
CANADIAN JOURNAL OF MICROBIOLOGY, 2001, 47 (07) :680-684